What is NVG-291?
NVG-291 is a peptide aimed at one of medicine's hardest problems: helping the brain and spinal cord repair themselves after injury. Developed by NervGen Pharma from a parent molecule called the intracellular sigma peptide, it targets a receptor called PTPsigma, a molecular brake that normally stops nerve fibers from growing through scar tissue.
The science is young, the ambition is enormous, and the honest status is: strong, consistent animal evidence, with the first human trials only recently completed. Few compounds in this library aim higher or sit earlier.
How does it work?
After a brain or spinal cord injury, the body lays down scar tissue rich in molecules called CSPGs, which act as a biochemical roadblock: they bind the PTPsigma receptor on nerve fibers and order growth to stop. That stop signal is a major reason central nervous system damage tends to be permanent.
NVG-291 modulates PTPsigma to ease that brake, giving nerve fibers a chance to grow past the scar and reconnect. The mechanism work even found the tool the cells use: releasing the receptor triggered secretion of an enzyme, cathepsin B, that helps digest the inhibitory scar molecules. Not just ignoring the roadblock, but clearing some of it.
Why it matters
Spinal cord injury, stroke damage, demyelinating disease: the central nervous system's refusal to regenerate sits behind some of the most life-altering conditions there are, and nothing approved today restores lost connections. A credible strategy for releasing the growth brake is therefore one of the most consequential ideas in regenerative neuroscience, which is exactly why a rigorous, patient reading of its evidence matters more here than anywhere.
What the research shows
The animal record is consistent across several injury models. A 2018 Journal of Neuroscience study showed PTPsigma modulation enhanced axon outgrowth by relieving CSPG inhibition and identified the cathepsin B mechanism. A 2019 study found the parent ISP strategy improved remyelination and functional recovery in demyelinated mice, restoring visual pathway conduction and acuity. A 2023 study in a rodent model of preterm brain injury reported better motor and cognitive outcomes, improved myelination, and a calmer inflammatory response.
The human program has begun: a Phase 1 safety study (NCT05308953) tested ascending doses in 74 healthy adults and completed, and the CONNECT study (NCT05965700), a Phase 1b/2a trial at the Shirley Ryan AbilityLab in Chicago, evaluated NVG-291 in people with chronic and subacute spinal cord injury, tracking electrophysiological measures of nerve transmission. Results from this earliest human work are what the field is watching for.
What people notice in practice
There is essentially no practice layer to report honestly: NVG-291 is a clinical-stage compound with no legitimate supply outside trials, and the spinal-cord-injury community following it is largely waiting rather than using. Where gray-market vials claiming to be NVG-291 or its parent peptide circulate, they carry the maximum version of the sourcing problem: an unapproved molecule, mid-trial, with no verified consumer synthesis anywhere.
The pros and the cons
What's promising
- A consistent animal record across spinal cord, demyelination, and brain-injury models.
- A mechanism that clears the growth roadblock rather than merely stimulating growth.
- Functional recovery in animals, not just fiber growth on slides.
- A real clinical program: Phase 1 completed, spinal-cord-injury trial run at a top rehabilitation center.
What's uncertain
- Everything human: no efficacy results in people have been established yet.
- CNS repair is the field where animal promise most often fails to translate.
- Optimal timing after injury, chronic versus fresh, is an open question the trial design itself probes.
- No approval anywhere, and no legitimate access outside trials.
Worth considering
- For spinal cord injury, trial enrollment is the legitimate route to this science.
- Gray-market vials claiming this molecule deserve maximum skepticism.
- Rehabilitation remains the evidenced foundation everything else builds on.
- Watch the CONNECT results; they will say more than any marketing ever could.
Why this one is worth watching
Most compounds in this library are old molecules waiting for trials nobody will fund. NVG-291 is the opposite: a young molecule with a funded sponsor actively running the trials, in an indication where success would be historic and failure would still teach the field something real. Either way, this is what the early chapters of a potentially important therapy look like while they are being written.
What the key studies tested
Our framing rule for evidence: a study tests one molecule, one model or population, one endpoint. Where the evidence sits:
Preclinical & practice
The full mechanism story: axon outgrowth, remyelination, functional recovery in rodents.
Early trials
Phase 1 safety in 74 healthy adults (completed); CONNECT Phase 1b/2a in spinal cord injury.
Late-stage trials
None yet.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Why doesn't the spinal cord heal on its own?
Partly because the body actively stops it: injury scar tissue is rich in CSPG molecules that bind the PTPsigma receptor on nerve fibers and signal growth to halt. That protective brake, useful in some contexts, is a major reason central nervous system damage tends to be permanent, and it is the exact target NVG-291 was designed to release.
Has NVG-291 helped any human patients yet?
Not provenly. The completed human work is a Phase 1 safety study in healthy adults and the CONNECT Phase 1b/2a trial in spinal cord injury, which tracked electrophysiological measures of nerve transmission. Establishing human efficacy is exactly what the coming phases are for; today the demonstrated recovery lives in rodent models.
Could this help stroke or MS as well?
The animal work says the mechanism is not injury-specific: the same strategy improved remyelination in demyelinated mice and outcomes in a brain-injury model. Those are directions the science could grow, resting today entirely on preclinical evidence. Spinal cord injury is where the human program actually is.
Can I get NVG-291?
Legitimately, only through clinical trials, and that is the honest full answer. It is an investigational compound mid-development with no approved product and no verified supply chain; anything sold under its name on the gray market is unverifiable at best. For those affected by spinal cord injury, trial participation and top-tier rehabilitation are the real doors.
What to take away
If you remember five things from this article, make them these:
- NVG-291 targets the molecular brake that stops nerve regrowth through scar tissue in the brain and spinal cord.
- The animal evidence is consistent and functional: growth, remyelination, and recovered behavior across models.
- Human testing has genuinely begun, through Phase 1 and a spinal-cord-injury trial at a leading center.
- No human efficacy is established yet, and CNS repair is where animal promise fails most often.
- There is no legitimate access outside trials, and the CONNECT results are the next thing worth waiting for.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. NVG-291 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.